ライフサイエンスコーパス: invariant chain

1 or histocompatibility complex [MHC] class II invariant chain).

2 urface form of CD74 (MHC class II-associated invariant chain).

3 ues in the lumenal domain of human and mouse invariant chain.

4 La cells expressing only the p33 form of the invariant chain.

5 -A(b) mice deficient in both cathepsin L and invariant chain.

6 g peptide(s), in mice deficient for H2-M and invariant chain.

7 gous to that used by the class II-associated invariant chain.

8 DQ, and MHC class II-associated genes DM and invariant chain.

9 d by the fate of the class II chaperone, the invariant chain.

10 , CLIP, derived from the class II-associated invariant chain.

11 -associated invariant chain peptides) of the invariant chain.

12 his particular combination also precipitates invariant chain.

13 presentation through the degradation of the invariant chain.

14 expressed marginal levels of cathepsin S and invariant chain.

15 ins increased cell surface expression of the invariant chain.

16 association with the class II MHC chaperone, invariant chain.

17 diates processing of MHC class II-associated invariant chain.

18 into the modular pairwise association of CD3 invariant chains.

19 and related molecules, including the MHC II invariant chain (-2.73-fold).

20 LECs express invariant chain and cathepsin L, but not H2-M, suggestin

21 major contributor to the interaction between invariant chain and class II molecules.

22 of Nef to up-regulate the expression of the invariant chain and DC-SIGN at the cell surface, whereas

23 tant but contribute to the modulation of the invariant chain and DC-SIGN, and are least critical for

24 o not express the MHC II accessory molecules invariant chain and DM, they are likely to load addition

25 oncurrent proteolytic processing of both the invariant chain and endocytosed proteins.

26 Coexpression of invariant chain and H-2M inhibit presentation of some, b

27 smic reticulum) are presented in the absence invariant chain and H-2M.

28 r CIITA and the CIITA targets, class II MHC, invariant chain and H2-DM (the murine equivalent of HLA-

29 cells by gamma-IFN induced the expression of invariant chain and HLA-DM alphabeta, thus facilitating

30 A-C, and the class II Ag presentation genes, invariant chain and HLA-DM, demonstrate that these prote

31 ecially cathepsins S and L, in degrading the invariant chain and regulating the convergence of proces

32 ult in the anomalous surface accumulation of invariant chain and the peptide-editing molecule H2-DM.

33 n S (Ctss), a cysteine protease that cleaves invariant chains and produces antigenic peptides for loa

34 scuss recent studies of the functions of TCR invariant chains and the contribution of the ten ITAMs t

35 antimature MHC class II antigen (lacking the invariant chain) and anti-CD20, both of which react with

36 lls transfected with genes for MHC class II, invariant chain, and DM, we have studied the contributio

37 r histocompatibility complex (MHC) class II, invariant chain, and DM.

38 (CLIP), a short proteolytic fragment of the invariant chain, and exhibit defective peptide-loading a

39 ents where the proper pH, proteases, MHC II, invariant chain, and HLA-DM reside, awaiting exogenous A

40 processing pathway, including class II MHC, invariant chain, and HLA-DMA/B genes.

41 ith promoters of immunoglobulin H chain, the invariant chain, and major histocompatibility complex cl

42 ification of an MHC-like compartment into an invariant chain- and MHC class II-rich complex of large

43 f CL or CS mediates efficient degradation of invariant chain as expected.

44 MHC class II molecules and invariant chain assemble at a neutral pH in the endoplas

45 ow demonstrate that unlike newly synthesized invariant chain-associated MHC-II, mature cell surface p

46 compatibility complex (MHC) and the class II invariant chain-associated peptide (CLIP) occurs natural

47 Invariant-chain binding also directs class II molecules

48 Invariant chain binds to class II molecules and guides t

49 served sequence in an unstructured region of invariant chain, binds in the peptide binding groove of

50 HeLa cells expressing class II molecules and invariant chain by transfection.

51 ptide and is not free to interact with CLIP, invariant chain can still bind the class II molecule at

52 ences do not result in altered regulation of invariant chain catabolism.

53 activating expression of the p41 isoform of invariant chain CD74, which inhibits viral entry by bloc

54 ne protease essential for degradation of the invariant chain CD74.

55 Proteomic analysis identified the invariant chain (CD74) as a key substrate of Sppl2a and

56 Invariant chain (CD74) mediates antigen-presenting cell

57 The invariant chain (CD74) mediates assembly and targeting o

58 The invariant chain (CD74), a chaperone in MHC class II-medi

59 major histocompatibility complex-associated invariant chain (CD74), parvalbumin, and galectin-3-was

60 es (Hippocampus) featured a highly divergent invariant chain (CD74).

61 biogenesis, and the MHC-class-II-associated invariant chain chaperone has been reported to regulate

62 after cathepsin-mediated degradation of the invariant chain chaperone molecule.

63 rimarily associated with nested fragments of invariant chain (class II-associated invariant chain pep

64 ntity of the lysosomal enzyme that initiates invariant chain cleavage is dependent on the class II MH

65 lection defect is due solely to the block in invariant chain cleavage we analyzed cathepsin L-deficie

66 these defects are due solely to the block in invariant chain cleavage, we used cathepsin-deficient B

67 the MHC class II complex with a fragment of invariant chain (CLIP) during maturation.

68 cules in association with a peptide from the invariant chain (CLIP).

69 igens in association with a peptide from the invariant chain (CLIP).

70 as developed that allows the screening of an invariant chain-complementary DNA fusion library in a ge

71 l proteolytic degradation of alphabeta dimer-invariant chain complexes (alphabeta.I) within human B c

72 d in the endoplasmic reticulum with class II-invariant chain complexes and appears to be maintained t

73 wly synthesized cathepsin D and MHC class II-invariant chain complexes enter a non-clathrin-coated ve

74 I complex assembly, containing both class II-invariant chain complexes in the process of invariant ch

75 ly synthesized MHC class II and MHC class II-invariant chain complexes initially reside in a detergen

76 e intermediates in the transport of class-II-invariant chain complexes to antigen-processing compartm

77 light the taut interactions between class-II-invariant-chain complexes and endosomal proteases during

78 By using an invariant chain construct with various peptides engineer

79 n be greatly improved by the introduction of invariant chain constructs containing a T helper epitope

80 he major histocompatibility complex class II invariant chain cytoplasmic tail, indicating that the ef

81 Invariant chain deficiency in Ldlr(-/-) mice reduced ath

82 igen presentation by CD1d are not reduced by invariant chain deficiency.

83 Invariant chain-deficient (Ii -/-) mice have impaired ab

84 P also was abolished using APC obtained from invariant chain-deficient mice, demonstrating Ag present

85 epithelial cells use cathepsin L (Cat L) for invariant chain degradation and MHC class II maturation.

86 d that murine Cat S plays a critical role in invariant chain degradation in intestinal epithelial cel

87 homozygous mutant and wild-type animals, and invariant chain degradation was not impaired by deletion

88 to the cell surface, but was generated after invariant chain degradation within lysosomal-like MHC-II

89 ment of cells with leupeptin, which inhibits invariant chain degradation, leads to the accumulation o

90 pendent, and thus imply it is independent of invariant chain degradation.

91 s modified at its carboxyl terminus with the invariant chain-derived Ii-Key peptide and at its N term

92 Unlike long-lived A(b)/class II-associated invariant chain-derived peptide (CLIP) complexes, mature

93 xpress class II bound by class II-associated invariant chain-derived peptide (CLIP), a short proteoly

94 are loosely occupied by class II-associated invariant chain-derived peptide and are SDS unstable.

95 ng was modified in the presence of exogenous invariant chain-derived peptide suggests that both bindi

96 sion and decreases the relative level of the invariant chain-derived peptide, CLIP, bound to surface

97 lyzes the release of MHC class II-associated invariant chain-derived peptides (CLIP) from class II mo

98 gen processing by catalyzing the exchange of invariant chain-derived peptides (CLIP) from class II mo

99 isense oligonucleotides directed against the invariant chain enhances the presentation of mRNA-encode

100 Invariant chain expression is also greatly reduced, but

101 Transient inhibition of invariant chain expression represents a simple and gener

102 This blockade resulted in the loss of the invariant chain fragment CLIP from the cell surface, sug

103 ng grooves were predominantly occupied by an invariant chain fragment or Ealpha(52-68) peptide, respe

104 HLA-DM catalyzes the release of invariant chain fragments from newly synthesized major h

105 partment(s) where antigenic peptides replace invariant chain fragments in the presence of the DM prot

106 The generation of invariant chain-free MHC class II molecules and their as

107 n the endocytic pathway following removal of invariant chain from class II molecules and before their

108 proteolytic removal of the chaperone protein Invariant chain from MHC-II, degradation of internalized

109 ic immune enhancer (truncated shark class II invariant chain) fused to the nonstructural (NS) protein

110 man cancers, by screening a melanoma-derived invariant chain fusion cDNA library with tumor-reactive

111 tion sequence (TAT) and to part of the human invariant chain, generating a modular antigen transporte

112 ion of MHC class I, beta2-microglobulin, and invariant chain genes was also found in these RFX-B-defi

113 n up-regulated ICAM-1, VCAM-1, MHC class II, invariant chain, H2-M, CD40, and B7-1 as determined by F

114 g., LMP2), transporters of antigen peptides; invariant chain, HLA-DM, and the costimulatory molecule

115 ing signals in the context of HLA-DM and the invariant chain (I chain) complexed to HLA-DR.

116 n presentation, including il12, MHC class II invariant chain iclp1, and csf1r.

117 Class II proteins associate with the invariant chain (Ii chain) and its derived class II-asso

118 ation pathway, namely, the MHC-II-associated invariant chain (Ii or CD74) and the peptide editor H2-D

119 up-regulate class II transactivator (CIITA), invariant chain (Ii) (p31 and p41), H-2Ma, and H-2Mb.

120 Invariant chain (Ii) also associates with MHC class I mo

121 We have studied the consequences of invariant chain (Ii) and DM expression on major histocom

122 tant in class II-restricted Ag presentation, invariant chain (Ii) and DM.

123 the class II-associated accessory molecules, invariant chain (Ii) and DM.

124 nd related antigen processing genes, such as invariant chain (Ii) and H2-DM accessory molecules, are

125 ) is facilitated by the accessory molecules, invariant chain (Ii) and H2-M.

126 lass II pathways require both MHC-associated invariant chain (Ii) and HLA-DM (H2-M in mice) chaperone

127 The independent influences of invariant chain (Ii) and HLA-DM molecules on the array o

128 lass II molecules with peptides requires the invariant chain (Ii) and the class II-like molecule H-2M

129 ed complexes of MHC II alphabeta dimers with invariant chain (Ii) are targeted to endosomes, where Ii

130 yeast two-hybrid system was used to identify invariant chain (Ii) as a cellular protein that interact

131 MHC class II and invariant chain (Ii) associate early in biosynthesis to

132 Invariant chain (Ii) associates with newly synthesized c

133 stocompatibility complex class II-associated invariant chain (Ii) binds to the active site of CatL an

134 proteases that not only destroy the class II invariant chain (Ii) chaperone but also generate the pep

135 The invariant chain (Ii) chaperone for MHC class II molecule

136 es, whereas biosynthetically immature MHC-II-Invariant chain (Ii) complexes are not.

137 patibility complex (MHC) class II-associated invariant chain (Ii) contains a 65 aa segment that binds

138 histocompatibility complex (MHC)-associated invariant chain (Ii) contains a single transmembrane dom

139 patibility complex (MHC) class II-associated invariant chain (Ii) contains an endoplasmic reticulum (

140 ine-based signals in the cytoplasmic tail of invariant chain (Ii) control targeting of newly synthesi

141 nd cathepsin L (catL) mediate late stages of invariant chain (Ii) degradation in discrete antigen-pre

142 invariant chain peptide (CLIP) region of the invariant chain (Ii) directly influences MHC class II pr

143 II major histocompatibility complex (Ia) and invariant chain (Ii) expression in the mouse intestinal

144 ired in this process both for degradation of invariant chain (Ii) from class II-Ii complexes to allow

145 ine-based motifs in the cytoplasmic tail and invariant chain (Ii) govern glycoprotein trafficking thr

146 nserted target Ag to MHC class II-associated invariant chain (Ii) greatly enhances both the presentat

147 The MHC class II invariant chain (Ii) has been used as an adjuvant to enh

148 patibility complex (MHC) class II-associated invariant chain (Ii) has long been implicated in both co

149 oexpression of the MHC II accessory molecule invariant chain (Ii) inhibited presentation of endogenou

150 Degradation of invariant chain (Ii) is a critical step in major histoco

151 Invariant chain (Ii) is a non-MHC-encoded molecule, whic

152 ted invariant chain peptide (CLIP) region of invariant chain (Ii) is believed to play a critical role

153 When invariant chain (Ii) is coexpressed with 81betaH-, the c

154 alent peptide (Ep), which in the presence of invariant chain (Ii) is extensively cleaved and replaced

155 lass II proteins and the class II-associated invariant chain (Ii) is important for proper MHC class I

156 T/E6 DNA with CIITA DNA and DNA encoding the invariant chain (Ii) linked to the pan HLA-DR-reactive e

157 ltering class II/CLIP affinity, we evaluated invariant chain (Ii) mutants with varying CLIP affinity

158 The invariant chain (Ii) plays a critical role in MHC class

159 The invariant chain (Ii) plays a critical role in the transp

160 In I-A(b) mice lacking the invariant chain (Ii) processing enzyme, cathepsin S, NK1

161 The invariant chain (Ii) promoter was used as a model to det

162 We studied the role of the invariant chain (Ii) protein's structure in its ability

163 patibility complex (MHC) class II-associated invariant chain (Ii) regulates intracellular trafficking

164 The invariant chain (Ii) targets major histocompatibility co

165 The invariant chain (Ii) targets newly synthesized major his

166 a glycosylation mutant of the p41 isoform of invariant chain (Ii) to evaluate the ability of ERAD to

167 DP(84Gly) does not bind invariant chain (Ii) via the class II-associated invaria

168 y, APC expression of HLA-DRalphabeta and the invariant chain (Ii) was associated with faster internal

169 itively selected in Ab-Ep [Ab-Ep transgenic, invariant chain (Ii)(-/-), I-A beta(b-/-)] mice, where I

170 ng pathway and in the proteolytic removal of invariant chain (Ii), a critical regulator of MHC class

171 ecreased abundance of the p35 isoform of the invariant chain (Ii), a human-specific chaperone protein

172 Invariant chain (Ii), a third chain which is associated

173 antigenic peptides after degradation of the invariant chain (Ii), an MHC class II-associated protein

174 s II major histocompatibility complex (MHC), invariant chain (Ii), and cathepsin L (CatL) molecules i

175 tivator, which have defects in MHC class II, invariant chain (Ii), and H-2M (DM) expression, are resi

176 llular expression of the class II chaperone, invariant chain (Ii), during the late stages (i.e., 8-10

177 late stage processing of MHC class II-bound invariant chain (Ii), enabling dissociation of Ii, and b

178 decreases in IFN-gamma induced expression of invariant chain (Ii), H-2Ma, and H-2Mb mRNAs.

179 ells, its chaperone, the class II-associated invariant chain (Ii), is degraded in a stepwise fashion

180 ssion of the MHC class II accessory molecule invariant chain (Ii), or deletion of the MHC class II cy

181 re expressed by transfection without DRbeta, invariant chain (Ii), or DMbeta.

182 d numerous inflammatory genes, including MHC invariant chain (Ii), vascular cell adhesion molecule-1,

183 associate in the endoplasmic reticulum with invariant chain (Ii), which (i) mediates the delivery of

184 partments by the class II accessory molecule invariant chain (Ii), which itself must be eliminated to

185 Invariant chain (Ii)-deficient mice exhibit profound B c

186 -DM heterodimers mediate the dissociation of invariant chain (Ii)-derived class II-associated Ii pept

187 cells exposed to rapamycin that also express invariant chain (Ii)-FKBP in the ER.

188 ts is mediated by their association with the invariant chain (Ii).

189 ir interactions with the class II chaperone, invariant chain (Ii).

190 l front requires the MHC class II-associated invariant chain (Ii).

191 pendent on the groove binding section of the invariant chain (Ii).

192 ts is mediated by their association with the invariant chain (Ii).

193 and glycoprotein 100 (GP100) tethered to the invariant chain (Ii).

194 mmune defense, we focused our studies on the invariant chain (Ii).

195 study, we found the association of FcRn and invariant chain (Ii).

196 hey do not coexpress the class II-associated invariant chain (Ii).

197 ef protein upregulates the expression of the invariant chain (Ii)/major histocompatibility complex cl

198 histocompatibility complex (MHC)-associated invariant chain (Ii; CD74), which was found to be highly

199 ains, alpha and beta, which assemble with an invariant chain, Ii, in the endoplasmic reticulum.

200 stocompatibility antigen class II-associated invariant chain Iip35 exhibits dibasic retention, carrie

201 ed the proteolytic processing of CD74 MHC II invariant chain in both cell types, causing dramatic bui

202 ly of CD1d1 in vivo, akin to the function of invariant chain in MHC class II assembly.

203 ptides (derived from the class II-associated invariant chain) in exchange for more stably binding pep

204 omal processing pathway, cathepsin S and the invariant chain, in the normal functioning of CD1.

205 D1d may be altered by class II molecules and invariant chain induced during inflammation.

206 Moreover, MHC II and the class II-associated invariant chain influence CD1d trafficking.

207 There, the class II-associated invariant chain is degraded, and peptides derived from i

208 ransported to a low pH compartment where the invariant chain is trimmed to the class II-associated in

209 This binding between class II/peptide and invariant chain is weak, and coprecipitation is only app

210 4, the cell-surface form of the MHC class II invariant chain, is a key inflammatory factor that is in

211 CD74, or the class II MHC-associated invariant chain, is best known for the regulation of Ag

212 rface isoform of the MHC class II-associated invariant chain, is one such molecule; its role remains

213 We show that the invariant chain (li, CD74) of the major histocompatabili

214 knockout DCs also accumulate high amounts of invariant chain-major histocompatibility complex (MHC) c

215 Accessory molecules, such as HLA-DM and invariant chain, modulate the ligands bound to MHC class

216 Cell-based vaccines consisting of invariant chain-negative tumor cells transfected with sy

217 the association with beta(2)-microglobulin, invariant chain of class II MHC, or patterns of glycosyl

218 and for the up-regulation of DC-SIGN and the invariant chain of MHC class II, but the role of the aci

219 was recently discovered and found to be the invariant chain of the HLA class II molecule, CD74.

220 sed activation motifs (ITAMs) present in the invariant chains of the TCR complex (TCR zeta and CD3-ga

221 ice show no differences in processing of the invariant chain or maturation of class II MHC products c

222 ulum (ER) via the N-terminal region of human invariant chain p33, with or without C-terminal KDEL, ma

223 derived from the cytoplasmic domain of human invariant chain (p33).

224 ted to a single peptide, class II-associated invariant chain peptide (CLIP) bound to H2-A(b).

225 ure of DQ2.5 is its high class-II-associated invariant chain peptide (CLIP) content.

226 Unlike the dominant role of one class II invariant chain peptide (CLIP) in blocking MHC class II,

227 The class II-associated invariant chain peptide (CLIP) region of invariant chain

228 The class II-associated invariant chain peptide (CLIP) region of the invariant c

229 ides engineered into the class II-associated invariant chain peptide (CLIP) region we have found that

230 riant chain (Ii) via the class II-associated invariant chain peptide (CLIP) region, nor does it prese

231 ragment of the Ii chain (class II-associated invariant chain peptide (CLIP) remains associated with c

232 etic exchange of the MHC class II-associated invariant chain peptide (CLIP) sequence with a sequence

233 Class II-associated invariant chain peptide (CLIP), a conserved sequence in

234 mice have predominantly class II-associated invariant chain peptide (CLIP)-, not antigenic peptide-b

235 (MHC) by release of class II MHC-associated invariant chain peptide (CLIP).

236 chain is trimmed to the class II-associated invariant chain peptide (CLIP).

237 ollowing dissociation of class II-associated invariant chain peptide (CLIP).

238 ssociated with a loss of class II-associated invariant chain peptide and leupeptin-induced protein in

239 urthermore, the level of class II-associated invariant chain peptide bound to HLA-DQ did not correlat

240 ability, suggesting that class II-associated invariant chain peptide does not play a direct role in t

241 ng a T helper epitope by class II-associated invariant chain peptide exchange.

242 ression and cell surface class II-associated invariant chain peptide expression, which suggests that

243 with covalently tethered class II-associated invariant chain peptide or other peptides which bind rel

244 f tetramers from I-A(g7)/class II-associated invariant chain peptide precursors by peptide exchange.

245 y conserved and recognize a peptide from the invariant chain peptide presented by MHC class II.

246 talyzing the exchange of class II-associated invariant chain peptide with the antigen-derived peptide

247 he invariant chain termed CLIP (MHC class II invariant chain peptide) presented on MHC class II molec

248 -kD peptide termed CLIP (class II-associated invariant chain peptide).

249 DM removes class-II-associated invariant-chain peptide (CLIP) from newly synthesized cl

250 the half-life of HLA-DR1class II-associated invariant-chain peptide complexes.

251 n resulted in a shift of class II-associated invariant-chain peptide release curves by up to 0.5 pH u

252 atalyzes the exchange of class II-associated invariant chain peptides (CLIP) for antigenic peptides.

253 coexpressed with surface class II-associated invariant chain peptides (CLIP) in human EBV-positive an

254 that are occupied by MHC class II-associated invariant chain peptides (CLIP), indicating deficient lo

255 e loading and accumulate class II-associated invariant chain peptides (CLIP).

256 ecules is assisted by HLA-DM, which releases invariant chain peptides from newly synthesized MHCII an

257 ass II binding fragment (class II-associated invariant chain peptides) of the invariant chain.

258 ents of invariant chain (class II-associated invariant chain peptides), and their interaction with HL

259 e of peptides, including class II-associated invariant chain peptides, from MHC class II molecules.

260 most peptides, including classII-associated invariant chain peptides.

261 II MHC molecules and, by destruction of the invariant chain, prepares the class II MHC molecule for

262 Inhibition of AEP activity slows invariant chain processing and hinders the expression of

263 Furthermore, we observed no effect on invariant chain processing following AEP inhibition for

264 ) haplotype which has little dependence upon invariant chain processing for peptide presentation.

265 Cathepsin L mediates invariant chain processing in cortical thymic epithelial

266 in B cells did not alter MHCII expression or invariant chain processing, but did perturb cytoplasmic

267 However, the details of invariant-chain processing and antigen processing may di

268 G/Ii-CIITA, with the MHC class II-associated invariant chain promoter driving CIITA expression.

269 a modified form of GAD under control of the invariant chain promoter resulting in efficient epitope

270 complex (MHC) class II molecules without the invariant chain protein (Ii) that normally blocks the an

271 athrin trimerization domain with that of the invariant chain protein, were able to self-assemble in r

272 determined that cathepsin S is necessary for invariant chain proteolysis in T cells.

273 owed that assembly, endosomal transport, and invariant chain proteolysis of mutant DR3 molecules were

274 nhibition of endosomal proteases critical to invariant chain proteolysis reveals marked shunting of c

275 -invariant chain complexes in the process of invariant chain proteolytic removal as well as mature pe

276 te action of low pH and HLA-DM displaces the invariant chain remnant CLIP or other peptides from the

277 resentation by catalyzing dissociation of an invariant chain remnant from the peptide binding groove

278 eta- and gammadeltaTCRs also differ in their invariant chain subunit composition, in that alphabetaTC

279 ffector T cells recognize a peptide from the invariant chain termed CLIP (MHC class II invariant chai

280 ffector T cells recognize a peptide from the invariant chain termed CLIP in association with major hi

281 ly plays a regulatory role in processing the invariant chain that is associated with the major histoc

282 les bind to an accessory protein, termed the invariant chain, that ensures proper folding of the mole

283 cathepsin S (CS), have been shown to process invariant chain, thereby facilitating MHC class II matur

284 cines do not express the accessory molecule, Invariant chain, they present MHC II-restricted peptides

285 ng occurs after endosomal degradation of the invariant chain to a approximately 3-kD peptide termed C

286 a significantly impaired the ability of this invariant chain to accumulate stably at the immunologica

287 nic peptides but also for proteolysis of the invariant chain to allow the maturation of class II MHC

288 of major histocompatibility complex class II invariant chain to endosomal compartments.

289 We have studied the ability of invariant chain to interact with a class II molecule in

290 heterodimers that had to associate with the invariant chain to reach endosomal compartments.

291 nto complexes containing endogenous beta and invariant chains, transported to the trans-Golgi network

292 ity of CD1d trafficking and suggest that the invariant chain was a component of ancestral antigen pre

293 The invariant chain was further essential for endosomal tran

294 antigen presentation, namely cathepsin S and invariant chain, was determined.

295 Because the vaccine cells lack invariant chain, we have hypothesized that, unlike profe

296 an upregulation of surface HLA-DR and CD74 (invariant chain), whereas CLIP was slightly but signific

297 ains associate with a protein chaperone, the invariant chain, which promotes the proper assembly of M

298 plasma membrane and the endosome, and by the invariant chain, with which CD1d associates in the endop

299 d extensive acquisition of MHC-II, H-2M, and invariant chain within 30 min, with concurrent degradati

300 te processing of the MHC class II-associated invariant chain within B cells and dendritic cells, and